ライフサイエンスコーパス: tolerance test

1 cose area under the curve in an oral-glucose-tolerance test).

2 raction from a mixed-meal or an oral glucose tolerance test).

3 ., a glucose clamp or an intravenous glucose tolerance test).

4 sing the Matsuda method from an oral-glucose-tolerance test.

5 ere then subjected to an intravenous glucose tolerance test.

6 SI was determined by intravenous glucose tolerance test.

7 abetes; mice were then given an oral glucose tolerance test.

8 men, respectively, completed an oral glucose tolerance test.

9 on, fasting glucose measurement, and glucose tolerance test.

10 nsitivity as measured by intravenous glucose tolerance test.

11 lso increases in response to an oral glucose tolerance test.

12 continued through a 3-h intravenous glucose tolerance test.

13 ing the insulin-modified intravenous glucose tolerance test.

14 was confirmed through an intravenous glucose tolerance test.

15 from frequently sampled intravenous glucose tolerance test.

16 ential postprandial responses to an oral fat tolerance test.

17 d fasting glucose determined by oral glucose tolerance test.

18 r glucose was measured after an oral glucose tolerance test.

19 rations were measured during an oral glucose tolerance test.

20 etion was measured by an intravenous glucose tolerance test.

21 h type 2 diabetes before and after a glucose tolerance test.

22 lucose test, and a confirmatory oral glucose tolerance test.

23 opic polypeptide were assessed during a meal tolerance test.

24 ing a frequently sampled intravenous glucose tolerance test.

25 ivity (n = 7) was measured using the insulin tolerance test.

26 tivity to insulin action measured by insulin tolerance test.

27 ostasis measured by means of an oral glucose tolerance test.

28 ified frequently sampled intravenous glucose tolerance test.

29 lerance after oral dosing in an oral glucose tolerance test.

30 es assessed by using a standard oral glucose tolerance test.

31 n the basal state and during an oral glucose tolerance test.

32 using both the oral and intravenous glucose tolerance tests.

33 v 131.7 mumol/L; P = 0.09), and oral glucose tolerance tests.

34 es status was assessed by using oral-glucose-tolerance tests.

35 n kinetics were calculated from oral glucose tolerance tests.

36 ively by intraperitoneal glucose and insulin tolerance tests.

37 te ratings were obtained throughout the meal tolerance tests.

38 ather than insulin resistance during insulin tolerance tests.

39 uired from human subjects undergoing glucose tolerance tests.

40 e was evaluated with intraperitoneal glucose tolerance tests.

41 icipants were diagnosed by 75 g oral glucose-tolerance tests.

42 estoring a physiological response to glucose tolerance tests.

43 ed to the study, including standardized meal tolerance tests.

44 trols underwent oral and intravenous glucose tolerance tests.

45 sphorylation of insulin receptor and glucose tolerance tests.

46 sting blood glucose measurements and glucose tolerance tests.

47 cemic clamp and intravenous and oral glucose tolerance tests.

48 ured by nonfasting blood glucose and glucose tolerance testing.

49 ell function, which was evaluated by glucose tolerance testing.

50 ex (DI) were assessed by intravenous glucose tolerance testing.

51 The latter is detected by oral glucose tolerance testing.

52 the obese subjects was documented by glucose tolerance testing.

53 curve for glucose during 2-hour oral glucose tolerance testing.

54 rred strategies were the 2-hour oral glucose tolerance test (100% effectiveness; $390 per case), 1-ho

55 eople who were screened with an oral glucose tolerance test, 196 (15%) had impaired glucose tolerance

56 ing the first 30 minutes of the oral glucose tolerance test 2 years later.

57 production (HGP) was examined using pyruvate tolerance tests, (2)H nuclear magnetic resonance spectro

58 lthy control subjects underwent a mixed-meal tolerance test (350 kcal) using a dual glucose tracer me

59 (insulin area under the curve during glucose tolerance test 609 +/- 103 vs. 313 +/- 66 ng mL(-1) min)

60 All underwent an oral glucose tolerance test, a liver panel, and a lipid profile.

61 glucose than wild-type (WT) mice in pyruvate tolerance tests, accompanied with enhanced expression of

62 a under the curve (AUC) from an oral glucose tolerance test, aerobic fitness (peak oxygen consumption

63 nsulin and glucose after a 75-g oral-glucose-tolerance test after 4 mo of treatment.

64 the early postpartum period via oral glucose tolerance testing after GDM, which is a time-consuming a

65 se disappearance rate on intravenous glucose tolerance test, all of which worsened minimally thereaft

66 lthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglycemic intraveno

67 color Doppler echocardiography, oral glucose tolerance test and blood biomarkers analyses were perfor

68 ression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin infusion.

69 nal diabetes (diagnosed with an oral glucose tolerance test and by criteria from the International As

70 nly improved the response to an oral glucose tolerance test and corrected insulin signaling but also

71 All underwent an oral glucose tolerance test and fasting lipoprotein subclasses measur

72 g the frequently sampled intravenous glucose tolerance test and insulin sensitivity using the hyperin

73 A glucose tolerance test and insulin tolerance test showed that 25

74 tivity, as insulin levels during the glucose tolerance test and insulin, leptin, and adiponectin leve

75 ition index were measured after oral glucose tolerance test and isoglycemic IV glucose injection (IGI

76 were determined from an intravenous glucose tolerance test and minimal modeling.

77 rticipants underwent a standard oral glucose tolerance test and provided detailed clinical, sociodemo

78 Participants underwent an oral glucose tolerance test and retinal imaging at 26-28 weeks gestat

79 ing the first 30 minutes of the oral glucose tolerance test and using the area under the curve of ins

80 s without diabetes underwent an oral glucose tolerance test and were observed until primary outcome (

81 Yet in insulin tolerance tests and euglycemic clamp experiments, NTE-1

82 by combining microdialysis with oral glucose tolerance tests and euglycemic-hyperinsulinemic clamps.

83 Glucagon action was examined using glucagon tolerance tests and glucagon-stimulated HGP, cAMP-respon

84 de of insulin secretion were used in glucose tolerance tests and in positron emission tomography anal

85 uppression of plasma FFA during oral glucose tolerance tests and insulin clamp in obese NGT and T2DM

86 Glucose or insulin tolerance tests and insulin signaling were performed in

87 sulin sensitivity was analyzed using insulin tolerance tests and insulin-stimulated phosphorylation o

88 olism investigations showed abnormal glucose tolerance tests and low HDL values in some patients, and

89 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) a

90 cose area under the curve in an oral glucose tolerance test, and AcAc predicted the conversion to typ

91 lipid levels, the results of an oral glucose tolerance test, and blood pressure were used to characte

92 ) using a clinical examination, oral glucose tolerance test, and gene expression and DNA methylation

93 lood glucose measurement, a 2-h oral-glucose-tolerance test, and record linkage to a reimbursement re

94 ma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell function.

95 ulin resistance, as confirmed by the insulin tolerance test, and to threefold higher levels of trigly

96 l laboratory testing, including oral glucose tolerance test, and ultrasonographic investigations of f

97 glucagon concentrations during oral glucose tolerance test, and, in vitro, by measuring glucose-stim

98 nd C-peptide levels, and glucose and insulin tolerance tests, and genetic deletion of hepatic FoxO1 r

99 sistance in glucose tolerance tests, insulin tolerance tests, and hyperinsulinemic-euglycemic clamp e

100 ear magnetic resonance spectroscopy, glucose tolerance tests, and plasma analyses.

101 We used fasting plasma glucose, glucose tolerance tests, and self-reported diabetes diagnoses or

102 easurement of glucose turnover; oral glucose tolerance test; and a liver biopsy.

103 nd insulin during an intraperitoneal glucose tolerance test; and Glut4 and ApoE expression in VAT.

104 ears that included 2-hour, 75-g oral glucose tolerance testing; anthropometry; and interviews.

105 a and whole-body insulin resistance (insulin tolerance test) as well as muscle oxidative stress, infl

106 She underwent tolerance tests, as food-dependent exercise-induced anap

107 r curve C-peptide response to the mixed meal tolerance test at 12 months (canakinumab trial) and 9 mo

108 pants (n = 170) underwent a 3-h oral-glucose-tolerance test at 30 wk (95% CI: 25, 33 wk) gestation an

109 l metabolism obtained during an oral glucose tolerance test at approximately 28 weeks' gestation, we

110 rface area burned, underwent an oral glucose tolerance test at discharge.

111 ulin will be measured during an oral glucose tolerance test at weeks 0 and 12.

112 Glucose tolerance testing at discharge offers an opportunity for

113 C-peptide concentrations during oral glucose tolerance tests at baseline and study end.

114 Oral glucose tolerance tests at discharge revealed that metformin sig

115 (GDM) during pregnancy from clinical glucose tolerance tests at median 28.1 weeks gestation.

116 and C-peptide measured by using oral-glucose-tolerance tests at the end of each diet.

117 RSM with three predonation RFs (oral glucose tolerance test, basal insulin, fasting plasma glucose) a

118 nt of insulin resistance and an oral glucose tolerance test-based index (Matsuda insulin sensitivity

119 mic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin resistance and

120 were less hyperinsulinemic during a glucose tolerance test because of reduced insulin secretion.

121 Participants also underwent glucose tolerance tests before and after intervention.

122 Washington DC, USA, who had had an exercise tolerance test between 1986, and 2011.

123 es were difference in change in oral glucose tolerance test between the groups and between baseline a

124 ed serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-mo

125 stionnaires, by fasting and 2-h oral-glucose-tolerance test blood glucose measurement at re-examinati

126 stionnaires; by fasting and 2-h oral-glucose-tolerance-test blood glucose measurement at re-examinati

127 (beta = 0.46, P = 0.00090) post oral glucose tolerance test, but only the latter passed Bonferroni co

128 In vivo, the intravenous glucose tolerance test characterized oxyntomodulin-induced insul

129 The glucose tolerance test clarified that the complex retained blood

130 d fasting hyperglycemia and impaired glucose tolerance test compared with wild-type mice.

131 ssue biopsies were obtained and oral glucose tolerance tests conducted.

132 BV at rest and during an intravenous glucose tolerance test demonstrated a sustained increase from 4

133 Glucose tolerance tests demonstrated that ATGL knockdown normali

134 d glucose production from pyruvate (pyruvate tolerance test), demonstrating defective hepatic glucone

135 In the independent cohort, only oral glucose tolerance test-derived indexes were associated with live

136 fasting glucose or insulin, or oral glucose tolerance test-derived measures.

137 area under the curve on 2-hour oral glucose tolerance test differed across arms (1-way ANCOVA P = 0.

138 nsitivity, show improvements in oral glucose tolerance tests, display reduced adipose tissue inflamma

139 did not change glucose tolerance or insulin tolerance tests done with pharmacological levels of insu

140 the LCT enhancer sequence in a large lactose-tolerance-tested Ethiopian cohort of more than 350 indiv

141 The analysis used metabolic cages, glucose tolerance tests, euglycemic and hyperglycemic clamps, as

142 In insulin tolerance test, exogenous insulin-induced suppression of

143 plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin r

144 plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin r

145 Oral tolerance tests for vitamin D2 (1,000 IU vitamin D2/kg)

146 y the frequently sampled intravenous glucose tolerance test (four cohorts) or euglycemic clamp (three

147 C-peptide of 0.4 nM or greater on mixed meal tolerance test from 11 sites in the USA.

148 r the curve C-peptide response to mixed meal tolerance test from baseline to 12 months.

149 SI by frequently sampled intravenous glucose tolerance test from entry to week 12.

150 to a frequently sampled intravenous glucose tolerance test (FSIGT) with the stimulator on and with t

151 fied, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated hepatic versus extr

152 d by frequently sampling intravenous glucose tolerance test (FSIVGTT).

153 ified frequently sampled intravenous glucose tolerance test (FSIVGTT).

154 ose tolerance (measured with an oral glucose tolerance test given after 90 min) and meal size (ad-lib

155 model assessment, and 2-h post-oral glucose tolerance test glucose and insulin levels.

156 nts with high-"normal" 2-h post-oral glucose tolerance test glucose levels display defects in insulin

157 During glucose tolerance tests, glucose disposal was enhanced in SIRT2

158 mice and observed no differences in glucose tolerance tests (GTTs) or insulin tolerance tests (ITTs)

159 cose >/=200 mg/dL during a 75-g oral glucose tolerance test had a definite diagnosis of type 2 diabet

160 d with glucose responses during oral glucose tolerance testing, HbA1c, beta-cell function, and insuli

161 plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to 1.05; P

162 -fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and/or antidiabe

163 during oral but not intraperitoneal glucose tolerance tests, highlighting the involvement of intesti

164 insulin action based on glucose and insulin tolerance tests, hyperinsulinemic-euglycemic clamps, and

165 T) followed by a 75-gram 2-hour oral glucose tolerance test if GCT result was >/=7.8 mmol/L.

166 In the oral glucose tolerance test, IL-1betaAb-treated CDs-HSD rats showed l

167 activity at rest and during an oral glucose tolerance test in obese metabolic syndrome (MetS) subjec

168 a GLP-1 concentration during an oral glucose tolerance test in rats.

169 ife and glucose tolerance in an oral glucose tolerance test in rodents.

170 the study sites and subject them to thermal tolerance testing in a controlled setting and find that

171 inings and performed intraperitoneal glucose tolerance testing in transgenic mice overexpressing hZnT

172 d sensitivity were defined from oral-glucose-tolerance tests in 86 overweight and obese subjects with

173 ted blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and high-fat fed Z

174 eritoneal sensors during intravenous glucose tolerance tests in eight swine.

175 lucose excursions in intraperitoneal glucose tolerance tests in mice with streptozotocin-induced (typ

176 wer fasting glucose levels, improved glucose tolerance test, increased lactate levels, reduced fat ma

177 loped systemic insulin resistance in glucose tolerance tests, insulin tolerance tests, and hyperinsul

178 as measured using an intraperitoneal glucose tolerance test (IPGTT).

179 equently assessed by intraperitoneal glucose tolerance test (IPGTT).

180 in glucose tolerance tests (GTTs) or insulin tolerance tests (ITTs) compared with wild-type mice of m

181 Intravenous glucose tolerance test IVGTT and OGTT insulin secretion rate (IS

182 ulinemic clamp (EHC), by intravenous glucose tolerance test (IVGTT) and by oral glucose tolerance tes

183 al model analysis of the intravenous glucose tolerance test (IVGTT) to document progression of resist

184 humans during an in-vivo Intravenous Glucose Tolerance Test (IVGTT).

185 glucose disposal during intravenous glucose tolerance tests (IVGTT) remains critical for stringent e

186 to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiate

187 e third ventricle during intravenous glucose tolerance tests (IVGTTs).

188 d insulin secretion [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four participants comple

189 se and insulin levels during an oral glucose tolerance test; levels of low-density lipoprotein (LDL)

190 Frequently sampled intravenous-glucose-tolerance tests measured insulin sensitivity (SI) and be

191 under the curve (AUC) following a mixed-meal tolerance test (MMTT) and flow cytometry.

192 rations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up.

193 AUC C-peptide following a 2-hour mixed-meal tolerance test (MMTT).

194 categorical nature and requires a mixed-meal tolerance test (MMTT).

195 glucose-potentiated arginine and mixed-meal tolerance tests (MMTTs), respectively, in pancreatic-suf

196 lucose levels were assessed during a glucose tolerance test (n = 2,264).

197 ntifying IGT/NODAT using 2-hour oral glucose tolerance test (n = 66), fructosamine was the most accur

198 and glucose metabolism status (oral glucose tolerance test; normal glucose metabolism [n=1269], pred

199 Plasma samples from intravenous glucose tolerance tests of 2.5- and 5-month-old GIPR(dn) transge

200 sults of a 26-28 week gestation oral glucose tolerance test) of women from the Born in Bradford study

201 ediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measurement over previ

202 ell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glu

203 g glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insulin clamp.

204 ous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic cl

205 nd labeled glucose infusion and oral glucose tolerance test (OGTT) before and 6 months after RDN.

206 beverage consumption during an oral glucose tolerance test (OGTT) for 400 northern European mothers

207 s conventionally confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of gestation, bu

208 e tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessions.

209 of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based population.

210 d that displayed activity in an oral glucose tolerance test (OGTT) in normal and diabetic mice.

211 .4 +/- 0.8 were subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days with the use of

212 n addition to 0-hour and 2-hour oral glucose tolerance test (OGTT) results, with measurement of gluco

213 We analyzed the results of an oral glucose tolerance test (OGTT) routinely performed before surgery

214 Sullivan test (POT) results, an oral glucose tolerance test (OGTT) was performed to diagnose GDM.

215 An oral glucose tolerance test (OGTT) was used to evaluate glucose contr

216 e, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with

217 l participants and underwent an oral glucose tolerance test (OGTT), a hypoglycemia questionnaire, and

218 peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chr

219 ucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydroc

220 Herein we describe oral glucose tolerance test (OGTT)-modeled beta-cell function and inc

221 mol/L (>/= 200 mg/dL) during an oral glucose tolerance test (OGTT).

222 subcutaneously 30 min before an oral glucose tolerance test (OGTT).

223 ng actions were tested after an oral glucose tolerance test (OGTT).

224 -cell function derived from the oral glucose tolerance test (OGTT).

225 es based on the rarely utilized oral glucose tolerance test (OGTT).

226 (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).

227 k 15, pigs were subjected to an oral glucose tolerance test (OGTT); blood glucose increased (P<0.05)

228 livery, parity, maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for Model 1 cova

229 Oral glucose tolerance testing (OGTT) has been mooted as an alternati

230 transplant recipients underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (baseline) and th

231 and who had undergone 2 or more oral glucose tolerance tests (OGTT) using grouped analyses and a cont

232 ic endpoints were explored with oral glucose tolerance tests (OGTT), serum lipid profiles, magnetic r

233 lenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postc

234 ibody was administered prior to oral glucose tolerance tests (OGTTs).

235 llected from frequently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29 recruited par

236 Two consecutive 5-h oral-lipid-tolerance tests (OLTTs) were conducted in 51 healthy adu

237 esponse to a glucose load applied in glucose tolerance tests on different days, promoted glucose upta

238 n, we performed oral and intravenous glucose tolerance tests on mutation carriers and matched control

239 uced insulinemic response to an oral-glucose-tolerance test over time with daily breakfast relative t

240 anthropometric examinations, an oral glucose tolerance test, overnight urine collection, a 12-lead re

241 P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10) trended toward being lower in

242 Intravenous glucose tolerance tests performed at 1, 2, and 3 or more months

243 All underwent oral glucose tolerance tests pre-LTx and serially post-LTx.

244 regnancy (2-h glucose after the oral glucose tolerance test; r(s) </= -0.21, P < 0.05).

245 e tolerance estimated by a 75-g oral glucose tolerance test result.

246 emic throughout the study, and their glucose tolerance test results were similar to control CD-1 mice

247 On the basis of oral glucose tolerance test results, participants were grouped into t

248 addition, body weight records and a glucose tolerance test revealed no differences between WT and PA

249 erinsulinemic-euglycemic clamp and a glucose tolerance test revealed no differences in insulin sensit

250 A pyruvate tolerance test revealed that PEMT deficiency greatly att

251 lycemic-euglycemic clamp studies and glucose tolerance testing revealed insulin resistance.

252 Finally, glucose and insulin tolerance testing revealed no alterations in glucose hom

253 Oral glucose tolerance tests revealed that male Znt7 KO mice fed the

254 The glucose tolerance test showed major improvement of the glucose c

255 A glucose tolerance test and insulin tolerance test showed that 25HC3S administration improve

256 ned during a frequently sampled i.v. glucose tolerance test showed that the antidiabetic effect of i.

257 Insulin tolerance tests showed that male Znt7 KO mice were insul

258 Glucose tolerance tests showed that Syn-1A-betaKO mice exhibited

259 Oral glucose and insulin tolerance tests showed that the compound improves glucos

260 recent-onset type 1 diabetes and mixed-meal-tolerance-test-stimulated C peptide of at least 0.2 nM.

261 se insulin release on an intravenous glucose tolerance test that was higher than the threshold.

262 In the oral glucose tolerance test, the chloroform extract exerted the highe

263 r therapy underwent cardiopulmonary exercise tolerance testing under 2 conditions in random sequence:

264 s and frequently sampled intravenous glucose tolerance tests using Bergman minimal model in children.

265 ecretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without d

266 <4.2 min) in response to intravenous glucose tolerance tests versus burst NO-releasing and control se

267 An oral glucose tolerance test was administered at discharge.

268 istance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.

269 Oral glucose tolerance test was considered the gold standard in ident

270 Intravenous glucose tolerance test was performed at baseline and at 4 and 18

271 A meal tolerance test was performed before (Pre) and after the

272 Oral glucose tolerance test was performed within 2 weeks after surger

273 Mixed-meal tolerance test was undertaken in parallel with HLA antib

274 A frequently sampled intravenous glucose tolerance test was used to obtain precise measures of ac

275 and rate sensitivity during the oral glucose tolerance test were measured with the model by Mari in 1

276 a lactose hydrogen breath test and a lactose tolerance test were performed after exclusion of primary

277 -euglycemic clamp and an intravenous glucose tolerance test were performed.

278 Lactose hydrogen breath test and lactose tolerance test were positive in all 7 patients (100%) in

279 Oral glucose tolerance tests were administered at the same time and l

280 re collected in the morning and oral glucose tolerance tests were done in accordance with a standard

281 Intravenous glucose tolerance tests were performed 2 weeks after surgery.

282 Physical examinations and oral glucose tolerance tests were performed at baseline and after 5 y

283 Intravenous glucose tolerance tests were performed before and after 1 and 6

284 Frequently sampled intravenous glucose tolerance tests were performed before and after interven

285 month-old offspring, and glucose and insulin tolerance tests were performed in the female offspring a

286 Body weights, plasma glucose, and insulin tolerance tests were performed prior to, immediately, an

287 Insulin and glucose tolerance tests were undertaken and hepatic AMPK activat

288 ormoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and

289 e were estimated by means of an oral glucose tolerance test, whereas peripheral insulin sensitivity a

290 KC islet grafts, postintrapertioneal glucose tolerance testing, whereas SC recipients remained hyperg

291 cipants underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling for

292 ucose homeostasis variables, and an oral-fat-tolerance test with measurement of plasma lipoproteins,

293 cose homeostasis parameters, and an oral fat tolerance test with measurement of plasma lipoproteins,

294 1,437 individuals underwent an oral glucose tolerance test with measurements of circulating glucose,

295 ts underwent a liver biopsy, an oral-glucose-tolerance test with minimal model analysis of glucose ho

296 ents underwent liver biopsy, an oral glucose tolerance test with minimal model analysis to yield gluc

297 ytokeratin-18 fragments, and an oral glucose tolerance test with minimal model analysis to yield gluc

298 Oral glucose tolerance testing with glucose, insulin, and C-peptide w

299 In oral glucose tolerance tests with diet-induced obese mice, NTE-1 trea

300 sitivity, as measured by glucose and insulin tolerance tests, with intermediate effects in Nat1 heter